CAJ | 학술논문

三阴性乳腺癌被定义为雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2（EGFR2）均阴性的乳腺癌，它具有独特的生物学特性及临床特征。大多数三阴性乳腺癌有基底细胞样表型的特点以及相同的临床病理特征，并且与遗传性基因 BRCA1相关。三阴性乳腺癌患者不同的亚群对于特定的靶向治疗有着不同的疗效。我们评估了三阴性乳腺癌化疗联合靶向治疗的方案，系统评价了 PubMed 数据库上对接受了化疗和靶向治疗的乳腺癌女性患者的随机临床试验报告。三阴性乳腺癌是一个对化疗敏感的实体肿瘤，单纯结合靶向药物并不能使疗效显著的提高，合理地选择病人，理性地结合靶向药物，才能使疗效更好。
삼음성유선암피정의위자격소수체（ER）、잉격소수체（PR）화인표피생장인자수체2（EGFR2）균음성적유선암，타구유독특적생물학특성급림상특정。대다수삼음성유선암유기저세포양표형적특점이급상동적림상병리특정，병차여유전성기인 BRCA1상관。삼음성유선암환자불동적아군대우특정적파향치료유착불동적료효。아문평고료삼음성유선암화료연합파향치료적방안，계통평개료 PubMed 수거고상대접수료화료화파향치료적유선암녀성환자적수궤림상시험보고。삼음성유선암시일개대화료민감적실체종류，단순결합파향약물병불능사료효현저적제고，합리지선택병인，이성지결합파향약물，재능사료효경호。
Triple -negative breast cancer (TNBC)is defined as the lack of immunohistochemical expression of the estrogen and progesterone receptors and human epidermal growth factor receptor 2 (EGFR2).Most TNBC has a basal-like molecular phenotype by gene expression profiling and shares clinical and pathological features with hereditaryBRCA1 related breast cancers.TNBC subgroups respond differentially to specific targeted agents.We evaluates the ac-tivity of available chemotherapy and targeted agents in TNBC.A systematic review of PubMed and conference databas-es was carried out to identify randomised clinical trials reporting outcomes in women with TNBC treated with chemo-therapy and targeted agents.TNBC being a chemosensitive entity,combination with targeted agents have not produced substantial improvements in outcomes.Appropriate patient selection with rationale combinations of targeted agents is needed for success.This article will review the concept and the treatment of triple -negative breast cancer.